



April 3, 2023

To whom it may concern:

Company Name: TAIYO HOLDINGS CO., LTD.
Representative: Eiji Sato, President and CEO
(Code: 4626 Listed on Prime Market of
Tokyo Stock Exchange)
Inquiries: Sayaka Tomioka, Executive Officer, General
Manager of Corporate Planning Department
Tel: +81-3-5953-5200 (main line)

Notice of Transfer of REMINYL[®] (galantamine) products in Japan

TAIYO HOLDINGS Co., Ltd. (hereinafter, “Taiyo Holdings”) hereby announces that its subsidiary TAIYO Pharma Co., Ltd. (hereinafter, “Taiyo Pharma”) today has entered into an agreement with Janssen Pharmaceutica NV (hereinafter, “Janssen”) to acquire the rights to the below-mentioned REMINYL[®] (generic name: galantamine hydrobromide) long-listed products* currently sold and distributed in Japan by Janssen’s affiliate Janssen Pharmaceutical K.K (such transaction, “Transfer”). Once all necessary procedures with the Ministry of Health, Labour and Welfare are completed, the marketing authorizations for REMINYL[®] will be transferred to Taiyo Pharma.

1. Reasons for the Transfer

The Medical and Pharmaceuticals Business of Taiyo Holdings has grown over time as the Taiyo Holdings group’s second pillar after our Electronics Business through the succession of eighteen long-listed products* by Taiyo Pharma and entry into contract manufacturing operations by TAIYO Pharma Tech Co., Ltd. As we stated in the “Beyond Imagination 2030” long-term business plan that it announced on June 4, 2021, Taiyo Holdings is engaged in a variety of initiatives with the aim of further growing its Medical and Pharmaceuticals Business.

REMINYL[®] is an acetylcholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. REMINYL[®] is a socially important pharmaceutical approved in Japan in 2011. Through the steady supply of REMINYL[®] to medical institutions and patients, Taiyo Pharma will endeavor to maintain product quality and collect information (e.g. safety information) as well as enhance the efficiency through its information-provision efforts and other business activities by enhancing its product lineup and strive to realize stable, ongoing operations as it moves forward.

2. Overview of the Transfer

(1) Assets in This Matter

This Transfer applies to the below long-listed products*, for which Janssen and its affiliates possess the manufacture and sales and distribution rights in Japan.

ENGLISH TRANSLATION OF JAPANESE-LANGUAGE DOCUMENT

This is a translation of the original Japanese-language document and is provided for convenience only.

In the event of any discrepancy between this translated document and Japanese original, the original shall prevail

	Product	Therapeutic Category
1	REMINYL [®] Tablets 4mg REMINYL [®] Tablets 8mg REMINYL [®] Tablets 12mg REMINYL [®] OD Tablets 4mg REMINYL [®] OD Tablets 8mg REMINYL [®] OD Tablets 12mg REMINYL [®] Oral Solution 4mg/mL ¹⁾	Therapeutic agent for Alzheimer dementia

1) REMINYL[®] Oral Solution 4mg/mL is distributed in three package configurations: 1mL, 2mL and 3mL.

(2) Operating Results of Assets in This Matter

This information is not disclosed per the agreement.

(3) Items for Assets in This Matter

Intangible assets, etc. are scheduled to serve as the assets in this matter.

(4) Value of Acquisition and Payment Method of Purchase Price

This information is not disclosed per the agreement.

3. Overview of Company Acquiring Assets (As of April, 2023)

(1) Name	TAIYO Pharma Co., Ltd.
(2) Location of Headquarters	Marunouchi North Exit Building, 14 th Floor 1-6-5 Marunouchi, Chiyoda-ku, Tokyo
(3) Name and Title of Representatives	Eiji Sato, Representative Director and CEO Masao Arima, Representative Director and COO
(4) Business Description	Development, manufacture, and sales business pertaining to pharmaceuticals for medical use, quasi-drugs, etc.
(5) Capital	JPY 450,000,000
(6) Date Established	August 2, 2017

4. Overview of Other Party (As of April, 2023)

(1) Name	Janssen Pharmaceutica NV
(2) Location of Headquarters	Turnhoutseweg 30 2340 Beerse, Belgium
(3) Name and Title of The Representative Person	Kris Sterkens, Managing Director
(4) Business Description	Research, development, manufacturing and sales of pharmaceutical products.
(5) Capital	56,845,933.93 EUR
(6) Date Established	October 23, 1934

5. Schedule

(1) Date of Conclusion of Asset Transfer Agreement	April 03, 2023
(2) Transfer of Marketing Authorizations	Once all necessary procedures with the Ministry of Health, Labour and Welfare are completed, the marketing authorizations for REMINYL [®] will be transferred to Taiyo Pharma.

6. Future Forecasts

The impact of the Transfer on Taiyo Holdings' consolidated financial results for the fiscal year ending March 31, 2024 will be minor. However, in May 2023, Taiyo Holdings will announce its earnings forecast for the fiscal year ending March 31, 2024, which will take into account the impact of this matter.

*At Taiyo Holdings, long-listed products are defined as original drugs whose patent period or reexamination period has ended, making it possible to sell them as generic drugs.

Overview of TAIYO HOLDINGS Co., Ltd.

Taiyo Holdings is a leading company that boasts the world's top market share of solder resist, a material used in printed wiring boards (PWB.) Based on the keyword of "chemicals," Taiyo Holdings has entered the medical and pharmaceuticals business to secure a second earnings base to follow our Electronics Business, which oversees the company's leading solder resist products. The Medical and Pharmaceuticals Business is developing by Taiyo Pharma Co., Ltd., which manufactures pharmaceuticals for medical use, and by Taiyo Pharma Tech Co., Ltd, which performs contract manufacturing for such pharmaceuticals. Going forward, in addition to reinforcing our existing businesses in order improve our medium- to long-term corporate value, Taiyo Holdings will focus on initiatives for creating new businesses on an ongoing basis.

Please visit <https://www.taiyo-hd.co.jp/en/> for more details about Taiyo Holdings.

Overview of TAIYO Pharma Co., Ltd.

Established as a wholly owned subsidiary of Taiyo Holdings on August 2, 2017, Taiyo Pharma will contribute to society through the development and expansion of our Medical and Pharmaceuticals Business with a focus on the manufacture and sale of long-listed products.

Please visit <https://www.taiyo-pharma.co.jp/> (Japanese language only) for more details about Taiyo Pharma.